Oct 21, 2020 • 8:05 am EDT Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020
Oct 8, 2020 • 8:05 am EDT Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates
Oct 6, 2020 • 7:05 am EDT Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint
Sep 8, 2020 • 7:05 am EDT Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
Aug 6, 2020 • 7:05 am EDT Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates
Aug 5, 2020 • 9:25 am EDT Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Jul 29, 2020 • 8:05 am EDT Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
Jul 8, 2020 • 8:05 am EDT Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors